Tomorrow Hearing FDA’s Emergency Research Rule–CNN News at 8:00 P.M will inform the public about how the FDA Rule impacts on American citizens who can be put at increased risk to test an experimental treatment without their knowledge or consent.
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Pharmaceutical industry corrupt practices are in evidence again, and again, and again.
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
To gain understanding as to why lethal drugs pass FDA review, read the front page article in The Wall Street Journal (below) describing the transformation of the FDA from watchdog to lapdog.
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
The Times’ humorous profile of JAMA’s editor attempts to trivialize the threat to public health when journals fail to maintain the integrity of science-based medicine.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
The law firm of Baum Hedlund filed a lawsuit against GlaxoSmithKline, the maker of the antidepressant, Paxil, for causing severe heart defects in the newborn son, of a woman prescribed Paxil during her pregnancy.
Today’s New York Times editorial hits the mark–it’s right on target!
